The Relationship of Prolactin and Inflammatory Markers With Parkinson's Disease Severity: Clinical and Biochemical Evaluation
试验速览
- 阶段
- 不适用
- 状态
- Enrolling By Invitation
- 发起方
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- Systemic inflammatory markers
研究概览
简要总结
This cross-sectional observational study aims to evaluate the relationship between serum prolactin levels, peripheral inflammatory markers (NLR, PLR, SII, CRP), and disease severity in patients with Parkinson's disease (PD). A total of at least 300 patients diagnosed with idiopathic PD will be included. Disease severity will be assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) and the Modified Hoehn-Yahr staging system. Serum and salivary prolactin levels will be measured using ELISA, while inflammatory markers will be calculated from routine blood tests. The study seeks to clarify whether prolactin and systemic inflammation indicators may serve as non-invasive biomarkers for disease progression and prognosis in PD, with particular emphasis on postmenopausal women.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Diagnosis of idiopathic Parkinson's disease confirmed by a neurologist
- •Both male and postmenopausal female patients
- •Patients able to provide informed consent
- •Clinically stable enough to undergo blood and saliva sampling, as well as neurological assessment
排除标准
- •Premenopausal female patients
- •Patients with secondary or atypical parkinsonism (e.g., drug-induced, vascular, atypical parkinsonian syndromes)
- •Known endocrine disorders affecting prolactin levels (e.g., prolactinoma, pituitary adenoma, hypothyroidism)
- •Use of medications known to alter prolactin secretion (e.g., antipsychotics, dopamine antagonists, estrogen therapy)
- •History of other neurodegenerative diseases (e.g., Alzheimer's, Huntington's)
- •Presence of active infection, chronic inflammatory disease, or malignancy
- •Severe renal, hepatic, or cardiac failure
- •Inability to provide informed consent
结局指标
主要结局
Systemic inflammatory markers
时间窗: 1 year later
NLR, PLR, SII, CRP
Prolactin Level
时间窗: 1 year later
Serum prolactine levels
次要结局
未报告次要终点
研究者
Hüseyin Avni Eroğlu
Assoc. Prof.
Çanakkale Onsekiz Mart University